TECOS: No CVD Risks or Heart Failure With SitagliptinTECOS: No CVD Risks or Heart Failure With Sitagliptin

The TECOS study showed sitagliptin was not associated with any signal of cardiovascular risk and, importantly, absolutely no increase in the risk of heart failure, a signal that has been observed with other DPP-4 inhibitors. Heartwire from Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news